Figure 1

Serum HBV DNA in Patients 0626-1537 and 0454-2506 Who Developed the rtN236T Mutation during ADV Therapy



Figure 2

Serum HBV DNA in Patients 0624-1517 and 0624-1564 Who Developed the rtA181V Mutation during ADV Therapy



(* The off-drug period from weeks 96 to 104 was due to a delay of approval of the clinical protocol amendment for the extension of the study to beyond 96 weeks.)

Figure 3

Serum HBV DNA in Patient 0370-3503 Who Developed rtK241E and rtK318Q Double Mutations